Injection of inactive Bordetella pertussis and complete Freund’s adjuvant with Torpedo californica AChR increases the occurrence of experimental autoimmune myasthenia gravis in C57BL/6 mice

References

• Appel SH, Almon RR, Levy N. Acetylcholine receptor antibodies in myasthenia gravis. N Engl J Med. 1975;293:760–761.
   PubMed Web of Science ®Google Scholar
• Lindstrom JM, Seybold ME, Lennon VA, et al. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976;26:1054–1059.
   PubMed Web of Science ®Google Scholar
• Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol. 2002;2:797–804.
   PubMed Web of Science ®Google Scholar
• Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science. 1973;180:871–872.
   PubMed Web of Science ®Google Scholar
• Noda M, Takahashi H, Tanabe T, et al. Primary structure of α-subunit precursor of Torpedo californica acetylcholine receptor deduced from cDNA sequence. Nature. 1982;299:793–797.
   PubMed Web of Science ®Google Scholar
• Noda M, Furutani Y, Takahashi H, et al. Cloning and sequence analysis of calf cDNA and human genomic DNA encoding α-subunit precursor of muscle acetylcholine receptor. Nature. 1983;305:818–823.
   PubMed Web of Science ®Google Scholar
• Boulter J, Luyten W, Evans K, et al. Isolation of a clone coding for the α-subunit of a mouse acetylcholine receptor. J Neurosci. 1985;5:2545–2552.
   PubMed Web of Science ®Google Scholar
• Karlin A. Molecular properties of nicotinic acetylcholine receptors. In: Colman CW, Poste G, Nicolson GL, editors. Cell surface and neuronal function. New York, NY: Elsevier/North-Holland Biochemical Press; 1980. p. 191–260.
   Google Scholar
• Changeux JP, Devillers-Thiery A, Chemouilli P. Acetylcholine receptor: an allosteric protein. Science. 1984;225:1335–1345.
   PubMed Web of Science ®Google Scholar
• Hucho F. The nicotinic acetylcholine receptor and its ion channel. Eur J Biochem. 1986;158:211–226.
   PubMedGoogle Scholar
• Sobel A, Weber M, Changeux JP. Large-scale purification of the acetylcholine-receptor protein in its membrane-bound and detergent-extracted forms from Torpedo marmorata electric organ. Eur J Biochem. 1977;80:215–224.
   PubMedGoogle Scholar
• McCormick DJ, Atassi MZ. Localization and synthesis of the acetylcholine-binding site in the α-chain of the Torpedo californica acetylcholine receptor. Biochem J. 1984;224:995–1000.
   PubMed Web of Science ®Google Scholar
• Atassi MZ, Mulac-Jericevic B, Yokoi T, et al. Localization of the functional sites on the alpha chain of acetylcholine receptor. Fed Proc. 1987;46:2538–2547.
   PubMedGoogle Scholar
• Hohlfeld R, Toyka KV, Tzartoss SJ, et al. Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor α subunit. Proc Natl Acad Sci USA. 1987;84:5379–5383.
   PubMed Web of Science ®Google Scholar
• Christadoss P, Lindstrom JM, Melvold RW, et al. Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis. Immunogenetics. 1985;21:33–38.
   PubMed Web of Science ®Google Scholar
• Bell J, Rassenti L, Smoot S, et al. HLA-DQ beta-chain polymorphism linked to myasthenia gravis. Lancet. 1986;i:1058–1060.
   Google Scholar
• Fuchs S, Nevo D, Tarrab-Hazdai R, et al. Strain differences in the autoimmune response of mice to acetylcholine receptors. Nature. 1976;263:329–330.
   PubMed Web of Science ®Google Scholar
• Christadoss P, Lennon VA, David C. Genetic control of experimental autoimmune myasthenia gravis in mice. I. Lymphocyte proliferative response to acetylcholine receptors is under H-2-linked Ir gene control. J Immunol. 1979;123:2540–2543.
   PubMed Web of Science ®Google Scholar
• Christadoss P, Poussin M, Deng C. Animal models of myasthenia gravis. Clin Immunol. 2000;94:75–87.
   PubMed Web of Science ®Google Scholar
• Pachner AR. Experimental models of myasthenia gravis: lessons in autoimmunity and progress toward better forms of treatment. Yale J Biol Med. 1987;60:169–177.
   PubMed Web of Science ®Google Scholar
• Oshima M, Maruta T, Ohtani M, et al. Vaccination with a MHC class II peptide in Alum and inactive pertussis strongly suppresses clinical MG in C57BL/6 mice. J Neuroimmunol. 2006;171:8–16.
   PubMed Web of Science ®Google Scholar
• Maruta T, Oshima M, Deitiker PR, et al. Use of Alum and inactive Bordetella pertussis for generation of antibodies against synthetic peptides in mice. Immunol Invest. 2006;35:137–148.
   PubMed Web of Science ®Google Scholar
• Engel AG, Tsujihata M, Lindstrom JM, et al. The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Ann N Y Acad Sci. 1976;274:60–79.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Lindstrom JM, Seybold ME. Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs. J Exp Med. 1975;141:1365–1375.
   PubMed Web of Science ®Google Scholar
• Yoshikawa H, Iwasa K, Satoh K, et al. FK506 prevents induction of rat experimental autoimmune myasthenia gravis. J Autoimmun. 1997;10:11–16.
   PubMed Web of Science ®Google Scholar
• Mulac-Jericevic B, Kurisaki J, Atassi MZ. Profile of the continuous antigenic regions on the extracellular part of the alpha chain of an acetylcholine receptor. Proc Natl Acad Sci USA. 1987;84:3633–3637.
   PubMed Web of Science ®Google Scholar
• Mulac-Jericevic B, Atassi MZ. Profile of the α-bungarotoxin-binding regions on the extracellular part of the α-chain of Torpedo californica acetylcholine receptor. Biochem J. 1987;248:847–852.
   PubMed Web of Science ®Google Scholar
• Berman PW, Patrick J. Experimental myasthenia gravis. A murine system. J Exp Med. 1980;151:204–223.
   PubMed Web of Science ®Google Scholar
• Zar JH. Biostatistical analysis. 2nd ed. Englewood Cliffs (NJ): Prentice-Hall; 1996.
   Google Scholar
• Oshima M, Pachner AR, Atassi MZ. Profile of the regions of acetylcholine receptor α chain recognized by T-lymphocytes and by antibodies in EAMG-susceptible and non-susceptible mouse strains after different periods of immunization with the receptor. Mol Immunol. 1994;31:833–843.
   PubMed Web of Science ®Google Scholar
• Lennon VA, McCormick DJ, Lambert EH, et al. Region of peptide 125–147 of acetylcholine receptor of α subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies. Proc Natl Acad Sci USA. 1985;82:8805–8809.
   PubMed Web of Science ®Google Scholar
• Atassi MZ, Ruan KH, Jinnai K, et al. Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide. Proc Natl Acad Sci USA. 1992;89:5852–5856.
   Google Scholar
• Yokoi T, Mulac-Jericevic B, Kurisaki J, et al. T lymphocyte recognition of acetylcholine receptor: localization of the full T cell recognition profile on the extracellular part of the α chain of Torpedo californica acetylcholine receptor. Eur J Immunol. 1987;17:1697–1702.
   PubMed Web of Science ®Google Scholar
• Matthys P, Vermeire K, Mitera T, et al. Enhanced autoimmune arthritis in IFN-γ receptor-deficient mice is conditioned by mycobacteria in Freund’s adjuvant and by increased expansion of Mac-1+ myeloid cells. J Immunol. 1999;163:3503–3510.
   PubMed Web of Science ®Google Scholar
• Shenoy M, Oshima M, Atassi MZ, et al. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region α146–162 of acetylcholine receptor. Clin Immunol Immunopathol. 1993;66:230–238.
   PubMedGoogle Scholar
• Pachner AR, Kantor FS, Mulac-Jericevic B, et al. An immunodominant site of acetylcholine receptor in experimental myasthenia gravis mapped with T-lymphocyte clones and synthetic peptides. Immunol Lett. 1989;20:199–204.
   PubMed Web of Science ®Google Scholar
• Milani M, Ostlie N, Wu H, et al. CD4+ T and B cells cooperate in the immunoregulation of experimental autoimmune myasthenia gravis. J Neuroimmunol. 2006;179:152–162.
   PubMed Web of Science ®Google Scholar
• Robinet M, Maillard S, Cron MA, et al. Review on toll-like receptor activation in myasthenia gravis: application to the development of new experimental models. Clin Rev Allergy Immunol. 2017;52:133–147.
   PubMed Web of Science ®Google Scholar
• Shenoy M, Goluszko E, Christadoss P. The pathogenic role of acetylcholine receptor α chain epitope within α146–162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice. Clin Immunol Immunopathol. 1994;73:338–343.
   PubMedGoogle Scholar
• Infante AJ, Thompson PA, Krolick KA, et al. Determinant selection in murine experimental autoimmune myasthenia gravis. Effect of the bm12 mutation on T cell recognition of acetylcholine receptor epitopes. J Immunol. 1991;146:2977–2982.
   PubMed Web of Science ®Google Scholar
• Bellone M, Ostlie N, Lei SJ, et al. The I-Abm12 mutation, which confers resistance to experimental myasthenia gravis, drastically affects the epitope repertoire of murine CD4+ cells sensitized to nicotinic acetylcholine receptor. J Immunol. 1991;147:1484–1491.
   PubMed Web of Science ®Google Scholar
• Oshima M, Atassi MZ. Effect of amino acid substitutions within the region 62–76 of I-Aβb on binding with and antigen presentation of Torpedo acetylcholine receptor α-chain peptide 146–162. J Immunol. 1995;154:5245–5254.
   PubMed Web of Science ®Google Scholar
• Rosenberg JS, Oshima M, Atassi MZ. B-cell activation in vitro by helper T cells specific to region α146–162 of Torpedo californica nicotinic acetylcholine receptor. J Immunol. 1996;157:3192–3199.
   PubMed Web of Science ®Google Scholar
• Atassi MZ, Oshima M. Autoimmune responses against acetylcholine receptor: T-B cell collaboration and manipulation by synthetic peptides. Crit Rev Immunol. 1997;17:481–495.
   PubMed Web of Science ®Google Scholar
• Nakayashiki N, Oshima M, Deitiker PR, et al. Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic T-cell epitope. J Neuroimmunol. 2000;105:131–144.
   PubMed Web of Science ®Google Scholar
• Oshima M, Deitiker P, Ashizawa T, et al. Vaccination with a MHC class II peptide attenuates cellular and humoral responses against tAChR and suppresses clinical EAMG. Autoimmunity. 2002;35:183–190.
   PubMed Web of Science ®Google Scholar
• Asthana D, Fujii Y, Huston GE, et al. Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis is mediated by IL-4 and antigen-specific T cell factors. Clin Immunol Immunopathol. 1993;67:240–248.
   PubMedGoogle Scholar
• Zhang GX, Xiao BG, Yu LY, et al. Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR. J Neuroimmunol. 2001;113:10–18.
   PubMed Web of Science ®Google Scholar
• Poussin MA, Fuller CL, Goluszko E, et al. Suppressed clinical experimental autoimmune myasthenia gravis in bm12 mice is linked to reduced intracellular calcium mobilization and IL-10 and IFN-gamma release by acetylcholine receptor-specific T cells. J Neuroimmunol. 2003;134:104–110.
   PubMed Web of Science ®Google Scholar
• Zhang GX, Navikas V, Link H. Cytokines and the pathogenesis of myasthenia gravis. Muscle Nerve. 1997;20:543–551.
   PubMed Web of Science ®Google Scholar
• Milani M, Ostlie N, Wang W, et al. T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci. 2003;998:284–307.
   PubMed Web of Science ®Google Scholar
• Shibaki A, Katz SI. Induction of skewed Th1/Th2 T-cell differentiation via subcutaneous immunization with Freund’s adjuvant. Exp Dermatol. 2002;11:126–134.
   PubMed Web of Science ®Google Scholar
• Cox JC, Coulter AR. Adjuvants-a classification and review of their modes of action. Vaccine. 1997;15:248–256.
   PubMed Web of Science ®Google Scholar
• Audibert FM, Lise LD. Adjuvants: current status, clinical perspectives and future prospects. Immunol Today. 1993;14:281–284.
   PubMedGoogle Scholar
• Rickman LS, Gordon DM, Wistar R Jr, et al. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet. 1991;337:998–1001.
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801.
   PubMed Web of Science ®Google Scholar
• Akira S. Innate immunity and adjuvants. Philos Trans R Soc Lond B: Biol Sci. 2011;366:2748–2755.
   PubMed Web of Science ®Google Scholar
• Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197–216.
   PubMed Web of Science ®Google Scholar
• Marta M, Meier UC, Lobell A. Regulation of autoimmune encephalomyelitis by toll-like receptors. Autoimmun Rev. 2009;8:506–509.
   PubMed Web of Science ®Google Scholar
• Billiau A, Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol. 2001;70:849–860.
   PubMed Web of Science ®Google Scholar
• Lu Y-C, Yeh W-C, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42:145–151.
   PubMed Web of Science ®Google Scholar
• Kerfoot SM, Long EM, Hickey MJ, et al. TLR4 contribution to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J Immunol. 2004;173:7070–7077.
   PubMed Web of Science ®Google Scholar
• Racke MK, Hu W, Lovett-Racke AE. PTX cruiser: driving autoimmunity via TLR4. Trends Immunol. 2005;26:289–291.
   PubMed Web of Science ®Google Scholar
• Fujimoto C, Yu CR, Shi G, et al. Pertussis toxin is superior to TLR ligands in enhancing pathogenic autoimmunity, targeted at a neo-self antigen, by triggering robust expansion of Th1 cells and their cytokine production. J Immunol. 2006;177:6896–6903.
   PubMed Web of Science ®Google Scholar
• Hou W, Wu Y, Sun S, et al. Pertussis toxin enhances Th1 responses by stimulation of dendritic cells. J Immunol. 2003;170:1728–1736.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Yang D, Chen Q, et al. Induction of dendritic cell maturation by pertussis toxin and B subunit differentially initiate Toll-like receptor 4-dependent signal transduction pathways. Exp Hematol. 2006;34:1115–1124.
   PubMed Web of Science ®Google Scholar
• Chen X, Winkler-Pickett RT, Carbonetti NH, et al. Pertussis toxin as an adjuvant suppresses the number and function of CD4 + CD25+ T regulatory cells. Eur J Immunol. 2006;36:671–680.
   PubMed Web of Science ®Google Scholar
• Uematsu S, Akira S. The role of Toll-like receptors in immune disorders. Expert Opin Biol Ther. 2006;6:203–214.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373–384.
   PubMed Web of Science ®Google Scholar
• Darabi K, Karulin AY, Boehm BO, et al. The third signal in T cell-mediated autoimmune disease? J Immunol. 2004;173:92–99.
   PubMed Web of Science ®Google Scholar
• Deitiker P, Ashizawa T, Atassi MZ. Antigen mimicry in autoimmune disease. Can immune responses to microbial antigens that mimic acetylcholine receptor act as initial triggers of myasthenia gravis? Hum Immunol. 2000;61:255–265.
   PubMed Web of Science ®Google Scholar
• Guler ML, Ligons DL, Wang Y, et al. Two autoimmune diabetes loci influencing T cell apoptosis control susceptibility to experimental autoimmune myocarditis. J Immunol. 2005;174:2167–2173.
   PubMed Web of Science ®Google Scholar
• Hamada Y, Takata M, Kiyoku H, et al. 2004. Monomethoxypolyethylene glycol-modified cardiac myosin treatment blocks the active and passive induction of experimental autoimmune myocarditis. Circ J. 68:149–155.
   PubMed Web of Science ®Google Scholar
• Amend B, Doster H, Lange C, et al. Induction of autoimmunity by expansion of autoreactive CD4 + CD62Llow cells in vivo. J Immunol. 2006;177:4384–4390.
   PubMed Web of Science ®Google Scholar